Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis

Taiwanese study found metformin use, vs non-users, was associated with higher risk of mortality (3.8 vs 3.3/100 patient-years; HR 1.13; 95% CI 1.01–1.25) and cirrhotic decompensation (5.9 vs 4.9/100 patient-years; 1.15; 1.04–1.27) in patients with compensated liver cirrhosis.

Source:

British Journal of Clinical Pharmacology